Background Multiple chemical sensitivity (MCS) has an estimated American prevalence of 15%, and no consistently abnormal laboratory tests are available to assist in its diagnosis. Some physicians treating MCS patients have observed changes in intra-erythrocytic minerals (IEMs). As co-factors, minerals could influence detoxication of xenobiotics.
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Aim
To test whether IEM differed comparing MCS cases with controls.
Methods
A total of 408 women meeting validated inclusion and exclusion criteria for MCS participated in this case-control study.
Introduction
Over 15% of American women report a perceived sensitivity to more than one chemical [1] . Clinicians with a special interest in multiple chemical sensitivity (MCS) have suggested that specific mineral deficiencies are consistent with some symptoms and metabolic problems found in MCS: chromium deficiency with sugar craving and hyperglycemia [2] , copper with anaemia and fatigue [3] , magnesium with fibromyalgia and chronic fatigue syndrome [4] , manganese with impaired glucose metabolism [5] , molybdenum with altered sulphite metabolism [6] , selenium with increased susceptibility to free radical damage [7] , sulphur with impaired detoxication [8] and zinc with impaired sense of smell [9] and sugar craving [10] .
To evaluate the role of minerals in MCS, intraerythrocytic mineral (IEM) analysis was undertaken as one component of a case-control study addressing other laboratory investigations in MCS [11, 12] . Our MCS case definition is based on previous research revealing that symptoms linked to a low-level exposure and reduced after removal of the exposure together with symptom chronicity differentiated 1337 patients in family medicine practices presumed to have a low risk of MCS, from 1247 in environmental practices presumably at higher risk. A stronger sense of smell than others have also discriminated between the two practices, and in the absence of that symptom, any two of feeling dull or groggy, feeling spacey and difficulty concentrating discriminated [13] .
Methods
Study design, ethics, case definition, exclusion and inclusion criteria and statistical methods have been described [11, 12, 13] . A total of 408 women age 25-64 years (216 cases, 192 controls) participated.
Fasting morning blood samples were drawn from recumbent participants into heparinized tubes and centrifuged; the buffy coat and plasma were removed. Red cells were washed three times with saline and then frozen. IEM analysis was done by Philip Analytical Services, an internationally accredited environmental laboratory network. Molybdenum and manganese were analysed by graphite furnace, mercury by cold vapour flameless atomic adsorption and remaining metals by inductively coupled plasma atomic emission spectrometry. Nine minerals (chromium, copper, magnesium, manganese, mercury, molybdenum, selenium, sulphur and zinc), hypothesized to be related to MCS (test panel), and another 12 with no prior hypotheses (routine Philip's panel) were measured.
For each mineral, proportions of cases and controls having detectable levels [per cent detectable (PD)] were compared (chi-square tests). Odds ratios for having detectable levels were estimated using logistic regression, with and without adjustment for potential confounders: age, smoking and birth in Canada. Means of detectable levels (MDL) were compared (t-tests with natural logarithm transformations for skewed data). Logistic regression examined the dose-response relationships between mineral levels (tertiles or quartiles) and probability of being a case. Tobit analyses included subjects with levels below the instrument detection limit and accommodated skewed distribution [11, 12] , yielding 'mean of all' (MOA) levels-detectable and undetectable.
Results
Cases and controls did not differ regarding age, marital status, educational background or daily or passive smoking. Cases were more likely to have been born in Canada (71 versus 52%, P 5 0.002) and to report recent nutritional supplement use (65 versus 51%, P 5 0.003).
As hypothesized for the test panel (Table 1) , PD, MDL, MOA were lower in cases for chromium and molybdenum. MDL were lower in cases for copper, magnesium, sulphur and zinc. However, differences were not statistically significant. Nor were there consistent or significant dose-response relationships before or after adjustment for confounding (Table 2) . Inconsistent with prior hypotheses were manganese, mercury and selenium results; the direction of casecontrol differences depended on the measure (PD, MDL or MOA). Inconsistencies were not explained by nutritional supplements. The same patterns were seen in users and non-users. No dose-response relationships were observed.
For the routine Philip's panel, only boron yielded significant findings lower in cases than controls. The MOA was lower, 1.37 versus 1.55 nmol/l 3 10 
Discussion
Using a valid and reproducible case definition [13] , our findings are consistent with prior hypotheses that cases would have lower levels of chromium, copper, magnesium, molybdenum, sulphur and zinc. Findings for mercury, selenium and manganese levels were inconsistent, although the observed higher manganese levels in cases align with the neurocognitive symptoms of MCS [14] . However, case-control differences were small and neither statistically nor clinically significant. Thus, multiple comparisons have not led to spurious significance for the test panel. Further, dose-response relationships, a major criterion for causality, were not observed, possibly due to prevalent rather than incident cases.
The significantly lower boron levels in cases, not explained by a prior hypothesis, may be a chance finding.
In conclusion, our results reveal no significant association between MCS and the test panel, and so IEM measurements do not appear to be useful objective diagnostic markers for MCS. Further studies could seek a biologic basis for small case-control differences observed in the test panel.
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